

Fusion Health Care launches new drugs to fight COVID-19

17 August 2020 | News

Launches Favipiravir drug under the brand name XARAVIR and an Immunity Booster product under the brand name D'FEND



Fusion Health Care, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

“It gives us immense satisfaction to launch ‘XARAVIR’ as this drug has the potential to save precious lives. We have launched the product at an affordable price and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market,” stated Mr. Madhu Ramadugu, Managing Director.

Fusion Health Care is known for its innovation - with many “First Time in India Products” which include – SCORBIX (Vitamin C 1.5 g Injection), DIFIDOX (Doxycycline Injection 100 mg) the No.1 brand in India predominantly used in treating Dengue, Malaria & Fever of unknown origin, STAPHONEX (Flucloxacillin Injection 1 g/500 mg), ISEP (Isepamicin Injection 200/400 mg) and many more.

The company has recently launched an Immunity Booster product under the brand name D'FEND. It consists of Vitamin C 1000 mg + Zinc 10 mg, available in sugar free orange flavour, in a tube of 20 effervescent tablets.

The role & benefits of Vitamin C + Zinc have been published in many established journals that indicate to improve immunity and avoid Flu.

Marking its 13th anniversary, Fusion Health Care inaugurated its R&D Facility in Hyderabad to bring innovative & affordable products for Indian Market.

Fusion Health Care has a strong Pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care & Cardio-Diabetes products.